Longeveron Inc
LGVN1.728USD
+0.093+5.68%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
25.85MCap. mercado
PérdidaP/E TTM
Más Datos de Longeveron Inc Compañía
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
Información de la empresa
Símbolo de cotizaciónLGVN
Nombre de la empresaLongeveron Inc
Fecha de salida a bolsaFeb 12, 2021
Director ejecutivoMr. Wa'el Hashad
Número de empleados25
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 12
Dirección1951 NW 7th Ave
CiudadMIAMI
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33136
Teléfono13053027158
Sitio Webhttps://www.longeveron.com/
Símbolo de cotizaciónLGVN
Fecha de salida a bolsaFeb 12, 2021
Director ejecutivoMr. Wa'el Hashad
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Chairman of the Board, Co-Founder, Chief Science Officer
Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.53K
+163.15%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
152.03K
+164.57%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
110.15K
+763.93%
Ms. Ursula Ungaro
Ms. Ursula Ungaro
Independent Director
Independent Director
35.55K
+91.64%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
29.59K
+135.01%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+318.71%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
21.00K
+425.00%
Ms. Neha Motwani
Ms. Neha Motwani
Independent Director
Independent Director
21.00K
+425.00%
Mr. Rock Soffer
Mr. Rock Soffer
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Chairman of the Board, Co-Founder, Chief Science Officer
Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.53K
+163.15%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
152.03K
+164.57%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
110.15K
+763.93%
Ms. Ursula Ungaro
Ms. Ursula Ungaro
Independent Director
Independent Director
35.55K
+91.64%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
29.59K
+135.01%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Por negocioUSD
Nombre
Ganancia
Proporción
Clinical trial revenue
259.00K
67.98%
Contract manufacturing lease revenue
116.00K
30.45%
Contract manufacturing
6.00K
1.57%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Clinical trial revenue
259.00K
67.98%
Contract manufacturing lease revenue
116.00K
30.45%
Contract manufacturing
6.00K
1.57%
Estadísticas de accionistas
Actualizado: vie., 1 de ago
Actualizado: vie., 1 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Armistice Capital LLC
5.00%
Lehr (Paul T)
2.44%
Hashad (Mohamed Wa'el Ahmed)
2.30%
Hare (Joshua M)
1.87%
Soffer (Rock J)
1.33%
Other
87.06%
Accionistas
Accionistas
Proporción
Armistice Capital LLC
5.00%
Lehr (Paul T)
2.44%
Hashad (Mohamed Wa'el Ahmed)
2.30%
Hare (Joshua M)
1.87%
Soffer (Rock J)
1.33%
Other
87.06%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
12.30%
Hedge Fund
5.00%
Investment Advisor
2.18%
Investment Advisor/Hedge Fund
1.49%
Research Firm
0.11%
Other
78.93%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
73
2.17M
16.04%
+290.03K
2025Q1
73
2.14M
15.82%
-119.71K
2024Q4
73
2.53M
18.80%
+652.31K
2024Q3
67
2.33M
17.58%
+1.38M
2024Q2
67
924.88K
16.16%
+194.99K
2024Q1
64
168.05K
15.95%
-258.83K
2023Q4
68
363.47K
37.19%
+110.22K
2023Q3
73
198.13K
31.46%
-72.89K
2023Q2
70
193.49K
31.19%
-39.22K
2023Q1
64
155.94K
27.45%
-36.93K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Armistice Capital LLC
676.23K
5%
+676.23K
--
Sep 30, 2024
Lehr (Paul T)
229.86K
1.7%
+98.89K
+75.50%
Jun 23, 2025
Hashad (Mohamed Wa'el Ahmed)
144.05K
1.06%
-10.99K
-7.09%
Apr 21, 2025
Hare (Joshua M)
253.07K
1.87%
-5.25K
-2.03%
May 16, 2025
Soffer (Rock J)
162.52K
1.2%
-23.00K
-12.40%
May 30, 2025
Locklear (Lisa)
57.96K
0.43%
-6.21K
-9.68%
Apr 21, 2025
Agafonova (Nataliya)
57.46K
0.42%
-7.56K
-11.63%
Apr 21, 2025
The Vanguard Group, Inc.
144.27K
1.07%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
140.73K
1.04%
+7.13K
+5.33%
Mar 31, 2025
Blass (Devin)
12.75K
0.09%
+12.75K
--
Apr 21, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Fecha
Tipo
Relación
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
